AL-15469A for the Treatment of Bacterial Conjunctivitis

Phase 3

Completed

• Conditions: Bacterial Conjunctivitis
• Interventions: Drug: Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%; Drug: Moxifloxacin hydrochloride ophthalmic solution 0.5% as base

• Registration Number: NCT00332293
• Lead Sponsor: Alcon Research

Brief Summary

The purpose of the study is to determine whether AL-15469A is safe and effective in the treatment of bacterial conjunctivitis.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-05
• Study First Submitted: 2006-05-31
• Study First Submitted QC: 2006-05-31
• Study First Posted: 2006-06-01
• Primary Completion: 2006-12
• Study Completion: 2006-12
• Status Verified: 2012-03
• Last Update Submitted: 2016-11-16
• Last Update Posted: 2016-11-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 695

Inclusion Criteria

• signs and symptoms of bacterial conjunctivitis
• Other protocol-defined inclusion criteria may apply

Exclusion Criteria

• under 1 mo. age
• Other protocol-defined exclusion criteria may apply

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Moxifloxacin	Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%	-
VIGAMOX	Moxifloxacin hydrochloride ophthalmic solution 0.5% as base	-

Primary Outcome Measures

Name	Time	Method
Clinical cure and microbiological success

Secondary Outcome Measures

Name	Time	Method
Individual signs and symptoms of bacterial conjunctivitis at each visit

Trial Locations

Locations (1)

Contact Alcon for Trial Locations; 🇺🇸 Fort Worth, Texas, United States